ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events:
| H.C. Wainwright 26th Annual Global Investment Conference | ||
| Speaker: | David Dodd, Chairman & CEO | |
| Date/Time: | September 9, 2024 at 7:00 a.m. ET | |
| Location: | Lotte New York Palace Hotel, New York, NY | |
| Webcast Link: | H.C. Wainwright Webcast | |
| Title: | GeoVax Corporate Update | |
Senior GeoVax management will host one-on-one meetings with registered attendees. If interested in meeting with management at this event, please contact the company through the conference portal, or directly at This email address is being protected from spambots. You need JavaScript enabled to view it..
| Emerging Growth Conference | ||
| Speaker: | David Dodd, Chairman & CEO | |
| Date/Time: | September 25, 2024 at 2:55 p.m. ET | |
| Location: | Virtual | |
| Webcast Link: | Emerging Growth Conference Webcast | |
| Title: | GeoVax Corporate Update | |
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
| 678-384-7220 | 212-698-8696 | 202-779-0929 |
| Last Trade: | US$2.20 |
| Daily Change: | -0.22 -9.09 |
| Daily Volume: | 550,976 |
| Market Cap: | US$20.770M |
December 09, 2024 November 26, 2024 November 19, 2024 November 12, 2024 August 28, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
